3-methoxy-1,8-naphthyridine-4-carbaldehyde | 893566-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-methoxy-1,8-naphthyridine-4-carbaldehyde
• CAS: 893566-53-5
• 化学式: C₁₀H₈N₂O₂
• 分子量: 188.186
• InChiKey: YERCYIKLUCSUOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-methoxy-1,8-naphthyridine-4-carbaldehyde 在 盐酸 作用下， 以 水 为溶剂， 反应 2.0h， 生成 3-hydroxy[1,8]naphthyridine-4-carbaldehyde hydrochloride
  参考文献：
  名称：

  Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections

  摘要：

  Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safety concerns, hepatotoxicity in particular. We have discovered a novel series of azetidinyl ketolides that focus on mitigation of hepatotoxicity by minimizing hepatic turnover and time-dependent inactivation of CYP3A isoforms in the liver without compromising the potency and efficacy of 1.

  DOI：

  10.1021/jm900729s
• 作为产物：
  描述：

  3-chloro-1,8-naphthyridine-4-carbaldehyde 、 sodium methylate 以 甲醇 为溶剂， 反应 1.0h， 以67%的产率得到3-methoxy-1,8-naphthyridine-4-carbaldehyde
  参考文献：
  名称：

  Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections

  摘要：

  Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safety concerns, hepatotoxicity in particular. We have discovered a novel series of azetidinyl ketolides that focus on mitigation of hepatotoxicity by minimizing hepatic turnover and time-dependent inactivation of CYP3A isoforms in the liver without compromising the potency and efficacy of 1.

  DOI：

  10.1021/jm900729s

文献信息

• [EN] ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES<br/>[FR] BENZO[B]AZÉPIN-2-ONES INHIBITRICES DE LA PROLIFÉRATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014009495A1

  公开（公告）日：2014-01-16

  Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3 and R4 are described in this application, and methods of using said compounds in the treatment of cancer.

  公开了公式(I)的化合物或其药物可接受的盐，其中W、X、Y、Z、R1、R2、R3和R4在本申请中有所描述，以及使用所述化合物治疗癌症的方法。
• Macrolides
  申请人：Chupak S. Louis

  公开号：US20060135447A1

  公开（公告）日：2006-06-22

  Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.

  本发明涉及以下Macrolide化合物及其定义，以及它们在动物中，包括人类中作为抗菌和抗原虫剂的用途：还公开了制备这些化合物、中间体和药物组成物的方法，以及通过将这些化合物用于需要的主体治疗或预防疾病的方法。此摘要仅为摘录，不限制本发明。
• ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150353499A1

  公开（公告）日：2015-12-10

  Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R 1 , R 2 , R 3 and R 4 are described in this application, and methods of using said compounds in the treatment of cancer.

  本发明涉及化合物I式或其药学上可接受的盐，其中W、X、Y、Z、R1、R2、R3和R4在本申请中有所描述，并且使用该化合物在癌症治疗中的方法。
• MACROLIDES
  申请人：Pfizer Products Incorporated

  公开号：EP1836211A1

  公开（公告）日：2007-09-26
• ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2872490A1

  公开（公告）日：2015-05-20